Goyal Monika K, Hersh Adam L, Badolato Gia, Luan Xianqun, Trent Maria, Zaoutis Theoklis, Chamberlain James M
Division of Emergency Medicine, Children's National Medical Center, Washington, DC; Department of Pediatrics, George Washington University, Washington, DC; Department of Emergency Medicine, George Washington University, Washington, DC.
Acad Emerg Med. 2015 Feb;22(2):192-6. doi: 10.1111/acem.12578. Epub 2015 Jan 29.
The objectives were to estimate the frequency of pregnancy testing in emergency department (ED) visits by reproductive-aged women administered or prescribed teratogenic medications (Food and Drug Administration categories D or X) and to determine factors associated with nonreceipt of a pregnancy test.
This was a retrospective cross-sectional study using 2005 through 2009 National Hospital Ambulatory Medical Care Survey data of ED visits by females ages 14 to 40 years. The number of visits was estimated where teratogenic medications were administered or prescribed and pregnancy testing was not conducted. The association of demographic and clinical factors with nonreceipt of pregnancy testing was assessed using multivariable logistic regression.
Of 39,859 sampled visits, representing an estimated 141.0 million ED visits by reproductive-aged females nationwide, 10.1 million (95% confidence interval [CI] = 8.9 to 11.3 million) estimated visits were associated with administration or prescription of teratogenic medications. Of these, 22.0% (95% CI = 19.8% to 24.2%) underwent pregnancy testing. The most frequent teratogenic medications administered without pregnancy testing were benzodiazepines (52.2%; 95% CI = 31.1% to 72.7%), antibiotics (10.7%; 95% CI = 5.0% to 16.3%), and antiepileptics (7.7%; 95% CI = 0.12% to 15.5%). The most common diagnoses associated with teratogenic drug prescription without pregnancy testing were psychiatric (16.1%; 95% CI = 13.6% to 18.6%), musculoskeletal (12.7%; 95% CI = 10.8% to 14.5%), and cardiac (9.5%; 95% CI = 7.6% to 11.3%). In multivariable analyses, visits by older (adjusted odds ratio [AOR] = 0.57, 95% CI = 0.42 to 0.79), non-Hispanic white females (AOR = 0.71; 95% CI = 0.54 to 0.93); visits in the Northeast region (AOR = 0.60; 95% CI = 0.42 to 0.86); and visits during which teratogenic medications were administered in the ED only (AOR = 0.74; 95% CI = 0.57 to 0.97) compared to prescribed at discharge only were less likely to have pregnancy testing.
A minority of ED visits by reproductive-aged women included pregnancy testing when patients were prescribed category D or X medications. Interventions are needed to ensure that pregnancy testing occurs before women are prescribed potentially teratogenic medications, as a preventable cause of infant morbidity.
本研究旨在评估育龄期女性在急诊科就诊时,接受或被开具致畸药物(美国食品药品监督管理局分类为D类或X类)后进行妊娠检测的频率,并确定未进行妊娠检测的相关因素。
这是一项回顾性横断面研究,使用2005年至2009年全国医院门诊医疗护理调查中14至40岁女性急诊科就诊的数据。估算接受或被开具致畸药物但未进行妊娠检测的就诊次数。使用多变量逻辑回归评估人口统计学和临床因素与未进行妊娠检测之间的关联。
在39,859次抽样就诊中,代表全国估计1.41亿次育龄期女性的急诊科就诊,1010万次(95%置信区间[CI]=890万至1130万)估计就诊与致畸药物的使用或开具有关。其中,22.0%(95%CI=19.8%至24.2%)进行了妊娠检测。未进行妊娠检测而使用最频繁的致畸药物是苯二氮䓬类药物(52.2%;95%CI=31.1%至72.7%)、抗生素(10.7%;95%CI=5.0%至16.3%)和抗癫痫药物(7.7%;95%CI=0.12%至15.5%)。与未进行妊娠检测而开具致畸药物相关的最常见诊断是精神疾病(16.1%;95%CI=13.6%至18.6%)、肌肉骨骼疾病(12.7%;95%CI=10.8%至14.5%)和心脏疾病(9.5%;95%CI=7.6%至11.3%)。在多变量分析中,年龄较大的女性(调整优势比[AOR]=0.57,95%CI=0.42至0.79)、非西班牙裔白人女性(AOR=0.71;95%CI=0.54至0.93);东北地区的就诊(AOR=0.60;95%CI=0.42至0.86);以及仅在急诊科使用致畸药物的就诊(AOR=0.74;95%CI=0.57至0.97)与仅在出院时开具药物相比,进行妊娠检测的可能性较小。
育龄期女性在急诊科就诊时,少数患者在被开具D类或X类药物时进行了妊娠检测。需要采取干预措施,以确保在女性被开具潜在致畸药物之前进行妊娠检测,作为预防婴儿发病的可预防原因。